OKYO Pharma Says Chief Medical Officer, Flavio Mantelli, Purchases 20,000 Of Its Ordinary Shares On NASDAQ At $1.40 Per Share
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced
A top doctor at OKYO Pharma bought 20,000 shares of the company's stock at $1.40 each. When leaders buy their own company's stock, it can signal they believe in what the company is doing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.